GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » 3-Year FCF Growth Rate

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) 3-Year FCF Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co 3-Year FCF Growth Rate?

Anhui Wanbang Pharmaceutical Technology Co's Free Cash Flow per Share for the three months ended in Mar. 2024 was ¥-0.22.

During the past 12 months, Anhui Wanbang Pharmaceutical Technology Co's average Free Cash Flow per Share Growth Rate was -99.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Anhui Wanbang Pharmaceutical Technology Co was 9.90% per year. The lowest was 6.00% per year. And the median was 7.95% per year.


Competitive Comparison of Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate falls into.



Anhui Wanbang Pharmaceutical Technology Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Anhui Wanbang Pharmaceutical Technology Co  (SZSE:301520) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Anhui Wanbang Pharmaceutical Technology Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Traded in Other Exchanges
N/A
Address
southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000
Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines